Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

BACKGROUND: Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment. Despite that erlotinib is considered to have a favorable safety profile, adverse events such as interstitial lung disease (ILD) were repor...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Makris, Demosthenes, Scherpereel, Arnaud, Copin, Marie Christine, Colin, Guillaume, Brun, Luc, Lafitte, Jean Jacques, Marquette, Charles Hugo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2007
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1963454/
https://ncbi.nlm.nih.gov/pubmed/17683587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-7-150
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller